for the fi rst time, the annual scientific meeting of the … · 2019. 5. 13. · ©overcome may...

1
©overcome MAY 8-9 2020 For the first time, the ANNUAL SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF CARDIOVASCULAR PHARMACOTHERAPY ( ISCP) will come to the US for its 25 TH congress ! www.iscp2020.com ISCP 2020 PRELIMINARY PROGAMME TOPICS Acute Coronary Syndromes STEMI Culprit Lesion vs Complete revascularization Stents Bioreabsorbable Scafflods Post PCI anticoagulants. Acute ischemic stroke. Novel approaches The Challenges of controlling blood pressure Non-Pharmacologic treatment. How much salt? Personalize blood pressure target. Digital medicine Obesity and hypertension. The dual threat New Concepts on Atrial Fibrillation Pharmacologic treatment (Who, How, When) The role of Anticoagulation in atrial fibrillation Prevention of Cardiovascular Disease Atherosclerosis and lipid management Diet and prevention of atherosclerosis Meet the experts: 1) Management of heart failure: Role of sacubitril valsartan 2) Anticoagulation in atrial fibrillation: when and how 3) Resistant hypertension: diagnosis and management 4) Digital Monitoring in hypertension 5) Sleep apnea management Pulmonary Hypertension Diagnosis and the role of RHC Management Pharmacological or SurgicalThe dual threat Heart Failure with Preserved EF Non-Pharmacologic management of HFpEF Therapies for HFpEF Point/Counterpoint Management of HFmEF 1) HFmEF should be treated as HFrEF 2) HFmEF should be treated as HFpEF Panel Discussion Lipid therapy or Anti- inflammatory therapy for atherosclerosis Lipid targets: HDL efflux capacity PCSK9- inhibitors (when) Inflation and atherosclerosis a new target Henry N. Neufeld Memorial Award Lecture Precision Medicine Cardiomyopathy update Utilization of Biomarkers in Heart Failure Management Approach to Myocarditis Amyloid and new therapies Lecture Hypertrophic Cardiomyopathy: Epidemiology and Management (B Maron) Heart failure update Guideline therapy for heart failure in clinical practice Present and future therapies for heart failure Targeting myocardial fibrosis in HFpEF Peripheral Arterial and venous Disease Management of PAD Management of Deep Venous Thrombosis Diagnosis and Management of Pulmonary Thromboembolic disease

Upload: others

Post on 14-Sep-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: For the fi rst time, the ANNUAL SCIENTIFIC MEETING OF THE … · 2019. 5. 13. · ©overcome MAY 8-9 2020 For the fi rst time, the ANNUAL SCIENTIFIC MEETING OF THE INTERNATIONAL

©ov

erco

me

MAY 8-92020

For the fi rst time, the ANNUAL SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF CARDIOVASCULARPHARMACOTHERAPY (ISCP) will come to the US for its 25TH congress!

w w w . i s c p 2 0 2 0 . c o m

ISCP 2020 PRELIMINARY PROGAMME TOPICS

Acute Coronary Syndromes

• STEMI Culprit Lesion vs Complete revascularization• Stents Bioreabsorbable Scaffl ods• Post PCI anticoagulants. • Acute ischemic stroke. Novel approaches

The Challenges of controlling blood

pressure

• Non-Pharmacologic treatment. How much salt?

• Personalize blood pressure target. Digital medicine

• Obesity and hypertension. The dual threat

New Concepts on Atrial Fibrillation

• Pharmacologic treatment (Who, How, When)• The role of Anticoagulation in atrial fibrillation

Prevention of Cardiovascular

Disease

• Atherosclerosis and lipid management• Diet and prevention of atherosclerosis• Meet the experts:

1) Management of heart failure: Role of sacubitril valsartan

2) Anticoagulation in atrial fibrillation: when and how3) Resistant hypertension: diagnosis and management4) Digital Monitoring in hypertension5) Sleep apnea management

Pulmonary Hypertension

• Diagnosis and the role of RHC• Management Pharmacological or SurgicalThe dual threat

Heart Failure with Preserved EF

• Non-Pharmacologic management of HFpEF• Therapies for HFpEF

Point/Counterpoint• Management of HFmEF

1) HFmEF should be treated as HFrEF2) HFmEF should be treated as HFpEF

Panel Discussion Lipid therapy or Anti-

infl ammatory therapy for atherosclerosis

• Lipid targets: HDL effl ux capacity• PCSK9- inhibitors (when)• Infl ation and atherosclerosis a new target

Henry N. Neufeld Memorial Award Lecture • Precision Medicine

Cardiomyopathy update

• Utilization of Biomarkers in Heart Failure• Management Approach to Myocarditis • Amyloid and new therapies

Lecture • Hypertrophic Cardiomyopathy: Epidemiology and Management (B Maron)

Heart failure update• Guideline therapy for heart failure in clinical practice• Present and future therapies for heart failure • Targeting myocardial fi brosis in HFpEF

Peripheral Arterial and venous Disease

• Management of PAD • Management of Deep Venous Thrombosis • Diagnosis and Management of Pulmonary Thromboembolic disease

For registration and abstract presentation, plase consult our website: www.iscp2020.com

For further information, please contact: Kim Ly, Project Manager - [email protected] - Tel: +33 (0)1 40 88 97 97Overcome: Offi cial PCO for ISCP 2020 - 13-15 rue des Sablons, 75116 PARIS - France